Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
43 /100
MEDIUM RISK
Score updated Aug 28, 2026

CGTX — Cognition Therapeutics, Inc. Dilution Risk Tracker

Track CGTX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track CGTX — Get alerts when the score changes →

As of August 28, 2026, Cognition Therapeutics, Inc. (CGTX) has a DilutionWatch DilutionScore of 43/100, rated MEDIUM dilution risk. Cognition Therapeutics, Inc. has a market capitalization of $105.61M, 95.09M shares outstanding, 75 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
40
📊 Float Risk
15
⚠️ Warrant Exposure
40
🔄 Convertible Debt
35

Dilution Forecast

Watch
Minor dilution signals detected
model est. 19%
🔄 Reverse Split model est. 30%
• 50-day avg $1.11 approaching $1 threshold
🔁 Convertible Conversion model 15%
• Convertible debt present: 11.8% potential dilution
🔔 Track CGTX — Get forecast alerts →

Market Data

Market Cap$105.61M
Shares Outstanding95.09M
Float81.85M
Cash$34.01M
Debt$638.0K
Short InterestN/A

Institutional Holdings

QoQ: ↑ 4.7% shares (2026Q1 vs prior)
75 institutional holders · 24.65M shares
#1 VANGUARD CAPITAL MANAGEMENT LLC 6.00M shares
#2 BIOS Capital Management, LP 6.00M shares
#3 DAVENPORT & Co LLC 2.89M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest8.93M
Days to Cover21.1
% of Float10.9%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2021-12-31
4 INSIDER TRANSACTION 2026-02-18
4 INSIDER TRANSACTION 2026-02-18
4 INSIDER TRANSACTION 2026-02-18
4 INSIDER TRANSACTION 2026-02-05
Full SEC filing analysis available with free account

Recent News

No recent news

Factual CGTX Dilution Snapshot

Cognition Therapeutics, Inc. (CGTX) has a DilutionScore of 43/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track CGTX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking CGTX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for CGTX
CGTX FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.